Collaboration planned to develop therapeutics potentially targeting multiple ophthalmic diseases leveraging APT’s PhageBank™ technology GAITHERSBURG, MD, June 10, 2021 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a newly-formed research collaboration with Oyster Point Pharma, Inc. (Nasdaq: OYST) for developing therapies, using APT’s PhageBank™ technology, potentially targeting […]
Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma to Target Ophthalmic Diseases
Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank™ in Urinary Tract Infections
GAITHERSBURG, Md., June 3, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in a Phase 1/2 study of bacteriophage therapy (PhageBank™) to evaluate the safety, tolerability, and efficacy of targeted, personalized, bacteriophage (“phage”) treatments in patients with urinary […]
Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing
GAITHERSBURG, MD., May 11, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed […]
Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis
GAITHERSBURG, MD, March 10, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies that address the global rise of multi-drug resistant infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for PhageBank™ phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO). “Advancing […]
Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections
– Phase 1/2 trial to be conducted at Mayo Clinic in Rochester, Minnesota, starting Q2 2021 – GAITHERSBURG, MD, February 10, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) […]
Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference
GAITHERSBURG, MD, January 15, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company will participate in the 17th Annual Small & Microcap Investor Conference (NobleCon17) being organized by Noble Financial Group, taking place virtually on January 19-20, 2021. Chief Executive Officer, Greg Merril, […]
FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections
A significant increase in mortality has been seen in COVID-19 patients with antibiotic resistant bacterial infections. APT has made available therapeutic phage treatment to physicians in the Rio Grande Valley of Texas who are treating COVID-19 patients with secondary Carbapenem Resistant Acinetobacter baumannii (CRAB) on an emergency basis Now the FDA has granted APT an Expanded […]
PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients
November 02, 2020 11:00 AM Eastern Standard Time Eight COVID-19 + CRAB patients have received PhageBank™ therapy under FDA-approved emergency allowance, with more anticipated Significant increased mortality has been observed from secondary CRAB infections in COVID-19 patients APT and its partners are currently self-funding emergency use of PhageBank™ in this patient group, and are seeking […]
Adaptive Phage Therapeutics Receives Orphan Drug Designation
Adaptive Phage Therapeutics (APT), announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing PhageBank™. Orphan drug designation is given to drugs and biologics being developed to treat rare medical conditions, specifically those affecting fewer than 200,000 persons in the U.S. Orphan […]
Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections
October 22, 2020 11:00 AM Eastern Daylight Time GAITHERSBURG, MD–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of multi-drug resistant infectious diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections […]